Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG1611 GENERATE for metastatic or recurrent pancreatic cancer
jRCTs031190009Phase 3Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- May 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel, gemcitabine, oxaliplatin, folinic acid, irinotecan and 2 more in pancreatic cancer (PC) (3 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Objective response rate in Arm C and Overall survival. Started May 2019; status: completed.
02
Drugs
paclitaxelgemcitabineoxaliplatinfolinic acidirinotecan
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCTs031190009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190009.